Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization
Tumori Journal · 2025
DOI: 10.1177/03008916251345409 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Tumori Journal, 2025. Verfasst von Daniele Lorenzini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, DNA Copy Number Variations, High-Throughput Nucleotide Sequencing, In Situ Hybridization. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Introduction
Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess ERBB2 (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing ERBB2 copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples.
Methods
We retrospectively reviewed the 531 cases evaluated by FoundationOne®CDx in our Institution, and HER2 status by IHC/ISH could be internally analyzed in 68 cases, including 31 (45.5%) gastroesophageal, 17 (25.0%) colorectal, four (5.8%) breast and two (2.9%) cholangiocarcinoma patients. Tumors with estimated ERBB2 copy number ⩾ 4 by FoundationOne®CDx, and tumors with strong and complete (3+) membranous staining by IHC and/or a HER2/CEP17 ratio ⩾2 by ISH were considered NGS positive and IHC/ISH positive, respectively.
Results
We identified 21 NGS positive cases (30.9%); IHC/ISH analysis confirming overexpression/amplification in 16 cases (sensitivity: 76.2%), while among the 47 NGS negative cases, 45 were confirmed by IHC/ISH results (specificity: 90%), with a positive predictive value of 76.2% and a negative predictive value of 95.7%.
Conclusions
FoundationOne®CDx provides an accurate evaluation of ERBB2 copy number status and may represent a cost-effective option in metastatic cancer patients for whom NGS testing is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
- Department of Oncology and Haematology-Oncology, University of Milan, Milan, Italy.
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ORCID-Profile: Desirè Viola Trupia, Federico Nichetti, Silvia Damian, Luca Agnelli, Andrea Vingiani, Giancarlo Pruneri
Zitieren
APA
Lorenzini, D., Salvatori, R., Volpi, C. C., Trupia, D. V., Niger, M., Nichetti, F., Duca, M., Damian, S., Busico, A., Bertolotti, A., Todoerti, K., Agnelli, L., Vingiani, A., & Pruneri, G. (2025). Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization. Tumori Journal. https://doi.org/10.1177/03008916251345409
Vancouver
Lorenzini D, Salvatori R, Volpi CC, Trupia DV, Niger M, Nichetti F, et al. Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization. Tumori Journal. 2025. doi:10.1177/03008916251345409
BibTeX
@article{Lorenzini2025,
author = {Lorenzini, Daniele and Salvatori, Rebecca and Volpi, Chiara Costanza and Trupia, Desirè Viola and Niger, Monica and Nichetti, Federico and Duca, Matteo and Damian, Silvia and Busico, Adele and Bertolotti, Alessia and Todoerti, Katia and Agnelli, Luca and Vingiani, Andrea and Pruneri, Giancarlo},
title = {Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization},
journal = {Tumori Journal},
year = {2025},
doi = {10.1177/03008916251345409}
}
EUVIMED